Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2010 Jan;8(1):95-106. doi: 10.1586/eri.09.123.

Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Author information

1
Texas Tech University Health Sciences Center, 1300 Coulter, Suite 203, Amarillo, TX 79106, USA. christopher.giuliano@ttuhsc.edu

Erratum in

  • Expert Rev Anti Infect Ther. 2010 Feb;8(2):250. Giulano, Christopher [corrected to Giuliano, Christopher].

Abstract

Vancomycin is a commonly used antimicrobial in patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Increasing vancomycin MIC values in MRSA clinical isolates makes the optimization of vancomycin dosing pivotal to its continued use. Unfortunately, limited data exist regarding the optimal pharmacokinetic-pharmacodynamic (PK-PD) goal to improve bacterial killing and clinical outcomes with vancomycin. The hallmark study in this area suggests that achieving an AUC to MIC ratio of over 400 improves the likelihood of achieving these outcomes. Challenges in the implementation of PK-PD-based dosing for vancomycin include current methodologies utilized in microbiology laboratories, as well as intra- and interpatient pharmacokinetic variability. Individualized dosing based on MIC and specific patient factors is important to achieve optimal outcomes from vancomycin therapy.

PMID:
20014904
PMCID:
PMC2877625
DOI:
10.1586/eri.09.123
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center